重组IL-1β疫苗减轻博来霉素诱导的小鼠肺纤维化
研究先验证人纤维化肺标本和小鼠气管内滴注博来霉素后肺组织IL-1β表达升高,并测试重组IL-1β的促炎促纤维化作用;随后设计抗IL-1β疫苗PfTrx-IL-1β,该疫苗耐受良好、诱导持久抗体反应并中和IL-1β活性,预免疫可保护小鼠免于博来霉素诱导的肺损伤、炎症和纤维化,且不损害抗感染免疫。
要点
- 人纤维化肺标本和小鼠博来霉素肺组织中IL-1β表达升高。
- PfTrx-IL-1β疫苗耐受良好,诱导持久抗体反应并中和IL-1β活性。
- 预免疫保护小鼠免于博来霉素诱导的肺损伤、炎症和纤维化。
核心结论
- 初步研究提示所制备的抗IL-1β疫苗有潜力开发为肺纤维化的治疗措施。
- 需要进一步实验评估IL-1β疫苗接种能否抑制慢性进展性肺纤维化并逆转已建立的肺纤维化。
研究设计与样本
- 研究先验证人纤维化肺标本和小鼠气管内滴注博来霉素后肺组织IL-1β表达升高,并在小鼠中测试重组IL-1β的促炎和促纤维化作用。
- 将两个IL-1β衍生多肽(已验证为介导IL-1β与其I型受体结合的关键结构域)整合入Pyrococcus furiosus硫氧还蛋白(PfTrx)设计抗IL-1β疫苗PfTrx-IL-1β,利用大肠杆菌表达系统制备融合蛋白。
主要发现
- 疫苗耐受良好,在小鼠中诱导强健且持久的抗体反应,并在细胞实验中中和IL-1β的生物学活性。
- 预免疫PfTrx-IL-1β有效保护小鼠免于博来霉素诱导的肺损伤、炎症和纤维化。
- 体外实验显示抗PfTrx-IL-1β抗体拮抗IL-1β在原代小鼠肺成纤维细胞、巨噬细胞(RAW264.7)和II型肺泡上皮细胞(A549)中促炎和促纤维化细胞因子产生的作用,以及原代小鼠肺成纤维细胞活化和肺泡上皮细胞上皮-间质转化(EMT)。
- 脓毒症模型验证接种未损害小鼠抗感染免疫。
局限性
- 原文为初步研究,需要进一步实验评估IL-1β疫苗接种能否抑制慢性进展性肺纤维化并逆转已建立的肺纤维化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interleukin-1β (IL-1β) contributes to interstitial lung disease (ILD) and pulmonary fibrosis (PF), thus representing a potential therapeutic target for PF. In this study, we first verified the increased expression of IL-1β in human fibrotic lung specimens and mouse lung tissues after intratracheal (i.t.) instillation of bleomycin (BLM), after which the pro-inflammatory and pro-fibrotic effects of recombinant IL-1β were tested in mice. The results above suggested that vaccination against IL-1β could be an effective strategy for managing PF. An anti-IL-1β vaccine (PfTrx-IL-1β) was designed by incorporating two IL-1β-derived polypeptides, which have been verified as the key domains that mediate the binding of IL-1β to its type I receptor, into Pyrococcus furiosus thioredoxin (PfTrx). The fusion protein PfTrx-IL-1β was prepared by using E. coli expression system. The vaccine was well tolerated; it induced robust and long-lasting antibody responses in mice and neutralized the biological activity of IL-1β, as shown in cellular assays. Pre-immunization with PfTrx-IL-1β effectively protected mice from BLM-induced lung injury, inflammation, and fibrosis. In vitro experiments further showed that anti-PfTrx-IL-1β antibodies counteracted the effects of IL-1β concerning pro-inflammatory and pro-fibrotic cytokine production by primary mouse lung fibroblast, macrophages (RAW264.7), and type II alveolar epithelial cell (A549), primary mouse lung fibroblast activation and epithelial-mesenchymal transition (EMT) of alveolar epithelial cells. In addition, the vaccination did not compromise the anti-infection immunity in mice, as validated by a sepsis model. Our preliminary study suggests that the anti-IL-1β vaccine we prepared has the potential to be developed as a therapeutic measure for PF. Further experiments are warranted to evaluate whether IL-1β vaccination has the capacity of inhibiting chronic progressive PF and reversing established PF.
引用
- Li H, Li Q, Hao Z, et al. A recombinant IL-1β vaccine attenuates bleomycin-induced pulmonary fibrosis in mice. Vaccine. 2024. PMID: 38714443. doi:10.1016/j.vaccine.2024.04.091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。